Biomerica Statistics
Total Valuation
Biomerica has a market cap or net worth of $7.38 million. The enterprise value is $6.24 million.
Important Dates
The last earnings date was Monday, April 13, 2026, after market close.
| Earnings Date | Apr 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biomerica has 3.09 million shares outstanding. The number of shares has increased by 18.46% in one year.
| Current Share Class | 3.09M |
| Shares Outstanding | 3.09M |
| Shares Change (YoY) | +18.46% |
| Shares Change (QoQ) | +3.51% |
| Owned by Insiders (%) | 10.23% |
| Owned by Institutions (%) | 3.62% |
| Float | 2.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.71 |
| Forward PS | n/a |
| PB Ratio | 2.18 |
| P/TBV Ratio | 2.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.64, with a Debt / Equity ratio of 0.06.
| Current Ratio | 2.64 |
| Quick Ratio | 1.46 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -94.32% and return on invested capital (ROIC) is -69.77%.
| Return on Equity (ROE) | -94.32% |
| Return on Assets (ROA) | -54.58% |
| Return on Invested Capital (ROIC) | -69.77% |
| Return on Capital Employed (ROCE) | -161.32% |
| Weighted Average Cost of Capital (WACC) | 5.62% |
| Revenue Per Employee | $80,130 |
| Profits Per Employee | -$77,296 |
| Employee Count | 54 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 2.51 |
Taxes
In the past 12 months, Biomerica has paid $22,000 in taxes.
| Income Tax | 22,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.52% in the last 52 weeks. The beta is 0.28, so Biomerica's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -23.52% |
| 50-Day Moving Average | 2.22 |
| 200-Day Moving Average | 2.50 |
| Relative Strength Index (RSI) | 56.49 |
| Average Volume (20 Days) | 20,244 |
Short Selling Information
The latest short interest is 63,380, so 2.05% of the outstanding shares have been sold short.
| Short Interest | 63,380 |
| Short Previous Month | 61,056 |
| Short % of Shares Out | 2.05% |
| Short % of Float | 2.28% |
| Short Ratio (days to cover) | 4.80 |
Income Statement
In the last 12 months, Biomerica had revenue of $4.33 million and -$4.17 million in losses. Loss per share was -$1.55.
| Revenue | 4.33M |
| Gross Profit | 189,000 |
| Operating Income | -5.35M |
| Pretax Income | -4.15M |
| Net Income | -4.17M |
| EBITDA | -5.27M |
| EBIT | -5.35M |
| Loss Per Share | -$1.55 |
Full Income StatementBalance Sheet
The company has $1.34 million in cash and $193,000 in debt, with a net cash position of $1.14 million or $0.37 per share.
| Cash & Cash Equivalents | 1.34M |
| Total Debt | 193,000 |
| Net Cash | 1.14M |
| Net Cash Per Share | $0.37 |
| Equity (Book Value) | 3.32M |
| Book Value Per Share | 1.09 |
| Working Capital | 2.56M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.17M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 83,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -3.17M |
| FCF Per Share | -$1.03 |
Full Cash Flow StatementMargins
Gross margin is 4.37%, with operating and profit margins of -123.67% and -96.46%.
| Gross Margin | 4.37% |
| Operating Margin | -123.67% |
| Pretax Margin | -95.96% |
| Profit Margin | -96.46% |
| EBITDA Margin | -121.75% |
| EBIT Margin | -123.67% |
| FCF Margin | n/a |
Dividends & Yields
Biomerica does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.46% |
| Shareholder Yield | -18.46% |
| Earnings Yield | -56.57% |
| FCF Yield | -42.96% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 21, 2025. It was a reverse split with a ratio of 1:8.
| Last Split Date | Apr 21, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
Biomerica has an Altman Z-Score of -14.88 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.88 |
| Piotroski F-Score | 2 |
